DPP-4的基因组学研究进展与DPP-4抑制剂的临床应用

发布时间：2018-06-20 08:06

本文选题：DPP- + 基因多态性　；参考：《中国医院药学杂志》2015年20期

【摘要】：二肽基肽酶IV(DPP-4)是一种分布广泛的膜相关性丝氨酸蛋白酶,能够影响糖代谢、脂质代谢、免疫调节、神经调节、信号转导、癌症发展等多种生理功能。随着全基因组关联研究(GWAS)的发展,DPP-4基因的基因多态性,主要是单核苷酸多态性已被证实影响血脂水平和mRNA表达,还影响心血管疾病的易感性,可能与DPP-4抑制剂在血脂紊乱和心血管疾病方面的疗效具有密切关系,这在2型糖尿病的治疗中具有重要意义。本文对国内外所有关于DPP-4基因多态性的研究进行综述,并在此基础上探讨其对DPP-4抑制剂在2型糖尿病治疗中的影响。
[Abstract]:Dipeptidyl peptidase (IVP) is a widely distributed membrane-associated serine protease, which can affect glucose metabolism, lipid metabolism, immune regulation, neuroregulation, signal transduction, cancer development and other physiological functions. With the development of genome-wide association study (GWAS), the polymorphism of DPP-4 gene, mainly single nucleotide polymorphism, has been proved to affect the level of blood lipid and mRNA expression, as well as the susceptibility to cardiovascular disease. It may be closely related to the efficacy of DPP-4 inhibitor in dyslipidemia and cardiovascular disease, which is of great significance in the treatment of type 2 diabetes. In this paper, we reviewed all the studies on the polymorphism of DPP-4 gene at home and abroad, and discussed the effect of DPP-4 inhibitor on the treatment of type 2 diabetes.
【作者单位】：山东大学药学院;青岛大学附属医院;山东大学附属山东省千佛山医院;
【分类号】：R96

【参考文献】